Gout

Ipsen (Paris:IPN) announced that commission European granted the authorization of the marketing for Adenuric(R) (febuxostat) for the treatment of the chronic hyperuricaemia in gout. Adenuric(R) opens way thus the first main alternative for gout, a severe illness debilitating of the treatment, for more than 40 years.

“the recent examinations confirm that the management of gout is frequent suboptimal, with less of the one than the half of the patients who receive the advice or urate appropriate from lifestyle that they lower the treatment” it said Michael Doherty, professor of rheumatology in the university of Nottingham (Joined Kingdom) and Co-chair of the force of task of 2006 EULAR for the recommendations in the diagnosis and management of gout. “the recommendations (EULAR) europias recent emfatizam the target” of the cure “lowering levels of urate of serum below of the point of saturation for the crystal formation. For some patients, urate existing that it lowers therapies has limitations in the terms of suitability or side effects. The availability of a new efficient therapy that allows that the target therapeutic either obtained improves armamentarium of the doctors and finally benefits the population of the patients with gout.”

Adenuric(R) (febuxostat) 80 120 of magnesium tablets of magnesium and is indicated for the treatment of the chronic hyperuricaemia for the circumstances where deposition of urate has occurred already (history including, or presence of, tophus and/or arthritis gouty).

Adenuric(R) will be introduzdo in the market for Ipsen in France. It are of France, commercialisation of the product will be partnered.

On the authorization of the marketing

(the European public summary of the report of the evaluation (EPAR) will be accessible in http://www.emea.europa.eu). This decision follows the filling for Ipsen, of an application for the authorization of the marketing for Adenuric(R) in the europia union in 2006. A positive opinion, recommending to grant an authorization of the marketing was adopted by the medicinal committee for products for the human use (CHMP) of the europia agency of the medicines (EMEA) in 21 February 2008.

The submission of I, enclosed two of the industry the greater sponsored studies to date to study the treatment of chronic patients of gout. The objective of the chronic treatment of gout is for guidelines of EULAR (it binds europia of meeting rheumatism) to reduce and to keep 6 levels of its below of mg/dL. Febuxostat demonstrated the superior ability to lower and to keep in the patients, acid uric of serum in an inferior of the the 6 level mg/dl compared with the conventionally used doses of allopurinol (febuxostat 80 and magnesium 120: 51 & 63 % of resp. against allopurinol: 22%). Beyond, a study of phase III it showed that the patients of gout with the soft one to moderate impairment renal (creatinine of serum > 1,5 -?2.0 mg/dl) had respectively had a tax of reply of 44 and 45 % with febuxostat 80 and magnesium 120.

On Adenuric(R) (febuxostat)

Gout, a particularly painful type of arthritis, is the arthritis most frequent in the men. Elevated of acid uric in the body is caused by levels: hyperuricaemia. Febuxostat, a verbal one, a time that-daily medication, is one non-non-purine of the novel, selective inhibitor of oxidase of xanthine studied for its effect in lowering levels of acid uric of serum (its) in the patients with gout.

The recommended verbal dose of Adenuric(R) is magnesium 80 a daily time without consideration to the food. If acid uric of serum will be > 6 mg/dl (357 mol/l) after 2-4 weeks, the magnesium(R) of Adenuric 120 a time daily can be considered. Works(R) of Adenuric enough quickly to allow to after reexamine of acid uric of serum 2 weeks. The 6 target therapeutic must diminish and keep acid uric of serum below of mg/dl (357?mol/l). The Prophylaxis of the widening of gout to little than 6 months is recommended in the initiation of treatment with Adenuric(R).

Febuxostat is permitted the Ipsen for EuropeTeijin limited Pharma, Tokyo. In 2003, Ipsen entered in a partnership of the research and the development with Teijin limited Pharma, in the company of the nucleus of the pharmaceutical business and home of the group of Teijin of healthcare. The group of Teijin is a Japanese industrial conglomerate that is specialized in the businesses of staple fibres, the films, plastics and the technology of information (IT) as.well.as pharmaceuticals and healthcare home. This partnership has covered the development and commercialisation subsequent of the four of products of Ipsen for Teijin Pharma in Japan and development and the marketing for Ipsen in Europe (that is europias union and Russia) of febuxostat, a possessed for Teijin Pharma and known product as TMX-67.

On Ipsen

Ipsen is a pharmaceutical group directed innovation of specialty international with on the 20 products in the market and a total team of employees worldwide of almost 4.000. Its strategy of the development is based on a combination of the products of specialty, that they are drivers of the growth, in whitened areas therapeutic (oncology, endocrinology and disorders to neuromuscular), and of the preliminary products of the care that significantly contribute its financing of the research. The position of its four centers of the research & the development (Paris, Boston, Barcelona, London) and its elasticity of the platform of the engineering of peptide and the protein the group one embroiders competitive in gaining the access to the main teams of research of the university and to the highly qualified staff. More than 700 peoples in the R&D are dedicated to the discovery and the development of innovative drugs for the patient care. This strategy is also supported by one active politics of the partnerships. In 2007, the development and research expenditure was sobre?185 million, in a consolidated excess of 20% of vendas, that atingiram?920.5 million when the total incomes atingiram?993.8 million. The parts of Ipsen are negotiated in the segment of Eurolist for EuronextTM (the code conserved in supply: IPN, ISIN code: FR0010259150). The parts of Ipsen are eligible to the “Service of Rglement Diffr” (”SRD”) and the group is part of the index of SBF 120. For more information in Ipsen, it visits our Web site in http://www.ipsen.com.

For ahead-looking at indications

The contained indications and targets for ahead-looking at in this are based on current opinions and assumptions of the management of Ipsen. Such indications involve the known and unknown risks and uncertainties that can make with that the real results, performance or events differ materially from those anticipated ones in this. Moreover, the process of the research and the development involves diverse periods of training in each one of that it has a substantial risk that the group will not obtain its objectives and will not force them to abandon its efforts in the respect of a product where invested significant additions. Consequently, the group cannot be certain that the favorable results gotten during experimentations pre-clinics will be confirmed subsequently during clinical experimentations, or that the results of clinical experimentations will be enough to demonstrate the safe and efficient nature of the concerned product, or that the authorities regulatory will be satisfied with the data and the information supplied by the company. Ipsen all contradicts express the obligation or to undertake to bring up to date or to revise any indications looking at forward, the targets or the estimates contained in this release of the press to reflect all the change in the events, the circumstances, the assumptions or the circumstances where indications are based, unless required thus for the applicable law. The business of Ipsen is subject to the sketched factors of risk in its filed originals of the information with the French financiers of the DES MarchsAutorit.

http://www.ipsen.com

Savient Pharmaceuticals, Incorporation (Nasdaq: Announced additional information of SVNT) related to the reactions and the deaths of infusion for its clinical experimentations of phase 3 for Puricase(R) (pegloticase) that he is being become for patients of gout of the imperfection of the treatment.

Severe and serious reactions of infusion

Our preliminary analysis indicated that 19 patients or 11% of pegloticase had treated patients had tried a reaction of infusion called “serious” or “severe.” Based in an information additional than if it became available, us we determine that the number of the patients who had tried “severe” or “serious” a reaction of infusion is 18, a reduction of 1 which had a patient whose the adverse event after occurred to break the clinical post-post-infusion of the place.

We also tell recently that 7 patients had tried “a severe” reaction of infusion. Of the 18 patients who had tried “a serious” or “severe” reaction of infusion, 5 had had “a serious” reaction of infusion that it was also characterized as “severe” in a way overlapping, since 7 patients had had “a severe” reaction of infusion that she also did not load the assignment of “serious.” Of the 6 remaining patients who had had “a serious” reaction of infusion, one was also told as “soft” and five had also been told as “it moderates.”

Additional information regarding the number of deaths of the patients

Of the 212 patients in Inteno–Trate the population (ITT), 158 patients finished all the visits. These 158 patients are enclosed in the analysis of the ITT, including 3 patients who had been attributed to the treatment of pegloticase that she died during the experimentation; drug did not become related it. A patient who randomized to the group of placebo died before the first administration of the dose of placebo and is not enclosed in the population of the ITT. Two patients who had finished the study, but had died the conclusion after, are enclosed also in the analysis of the ITT. We learn recently that one of these two patients estve attributed to an arm of the treatment of pegloticase and the other estve attributed placebo. The death of this last patient occurred 4 months after the administration of placebo.

It must be indicated that the company does not look for for is post-studies the information of the continuation in the patients who had left to fall outside of the experimentation, or she was not registered in the open extension of the label. However, if the death of a patient will be told to the company later that the patient had a final visit (a drop for is or a finished patient), this death will be enclosed then in the accounting of patient disposals in our submissions and reports regulatory. We are liberating this information in this time because we understand that a number our shareholders and of members of the community of the analyst are interested better in understanding these editions. However, we do not undertake no commitment to continue to divulge the information of this luck.

The company is programmed to liberate resulted financial for the room room and the 2007 year-end that they follow the end of the market in tuesday, March 11, 2008 and will house a call of conference of the community of the investment that starts in 10:00 a.m. Eastern time March in 12, 2008.

On Puricase(R) (pegloticase)

Puricase is pegylated oxidase mammalian recombinant of urate in the development to control the hyperuricemia and its clinical consequences in the patients for who the conventional therapy is contraindicated or had been inefficacious. The 3 two-phase experimentations pivotal had evaluated the security and efficacy of a course of six months of the therapy of pegloticase in the patients with gout of treatment-fails under the auspices of a special evaluation of the protocol of the administration of the food and the drug of United States. Savient permitted right worldwide to the related technology the PuricaseDuque Universidade and Mountain Mountain View Pharmaceuticals, Puricase Incorporation is a registada registered mark of pharmaceuticals of the Mountain View, Inc..

On The Population Of The Gout Of Tratamento-Falha

Approximately three to the Americans of five-million suffer from gout, many of who the experience only limited the success in the management in the long run of its painful symptoms. Inside of this group, us we esteem that allopurinol, mainstay of the therapy for the control of acid uric, is contraindicated or we do not obtain the appropriate success approximately therapeutic in dosages in the 25,000 100,000 patients, meaning that today the ten of the thousands of patients of gout do not have no efficient option of the treatment. It is for these patients of treatment-fails that pegloticase offers to potential an original benefit and for which the product was granted to the assignment orphan of the drug.

On PharmaceuticalsSavient, Inc..

Pharmaceuticals of Savient is a connected biopharmaceutical company in developing and distributing the products pharmaceutical that whiten medical necessities of unmet in niche and in wider markets. The candidate of the development of product of the company, Puricase (pegloticase) for gout of treatment-fails, told 3 positive clinical data of phase 1, 2 e. The patient who dosing in the clinical studies of phase 3 started in June 2006; the patient register was finished in March 2007; e the clinical studies of phase 3 had been finished in October 2007. Pegloticase changedded official the generic name for Puricase attributed for the USAN advice that substitutes the previously used name of the Peg-uricase. The tried team of the management of Savient is committed to advance its plumbing and to in- expand its portfolio of the product for composites being permitted of the late-period of training and to explore the chances of co-co-promotion and the co-development that fit the skill of the company in pharmaceuticals and in biopharmaceuticals of specialty with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (tablets of oxandrolone, USP) CIII in And U.. A additional information in Savient can be reached visiting: http://www.savient.com.

For Diante-Olhando the Language

All the indications to the exception of the indications of the enclosed historical facts in this release of the press regarding the security or the foreseen Puricase, our interpretation of the results and other developments (adverse events including) that if they relate our clinical experimentations of phase 3 for Puricase, aprova0 regulatory for Puricase, and plants and objectives of the management for ahead- are looking at indications inside of meaning of the confidential act of the reform of litigation of seguranas of 1995 and are citizens the definitive risks, trends and uncertainties that they could make with that the results and the accomplishments Reals differ materially from those expressed in such indications. These risks, trends and uncertainties are in some examples beyond our control. The words as “they anticipate,” “believe,” “estimative,” “wait,” “intend,” “plant,” “” and other similar expressions help to identify ahead-to look at indications, even so all the indications for ahead-looking at do not contain these words identifying. These indications for ahead-looking at involve substantial risks and uncertainties and are based on expectations, assumptions, estimates and current projections. The important factors that they can affect our ability to ahead- obtain the substances directed in these indications for being looked at include, but they are not limited, an information additional than either identified in the revision continuing of the results and other developments (adverse events including) that our clinical experimentations for Puricase become related, the risk of phase 3 that the FDA does not approve the marketing of Puricase, and other factors entirely determine more in our reports filed with commission of seguranas and exchange, that investors is consulted for a additional information. We cannot really obtain the plants, the intentions or the expectations divulged in our indications for ahead-looking at, and you do not have to ahead- place reliance improper in our indications for being looked at that they only speak as of the date of publication of this annual report to the shareholders. The real results or events could differ materially from the plants, the intentions and the expectations divulged in the indications for ahead-looking at that we make. We do not have one politics to bring up to date or to revise indications for ahead-looking at e, except as necessary for the law, we do not assume no obligation to bring up to date nenhumas indications for ahead-looking at.

PharmaceuticalsSavient

Ipsen (Paris:IPN) announced that the medicinal committee for products for the human use (CHMP) of the europia agency of the medicines (EMEA) supplied to a positive opinion Adenuric(R) (febuxostat) 80 120 of magnesium tablets of magnesium and the treatment of the chronic hyperuricaemia in gout and recommended it for the authorization of the marketing. The CHMP recommendation will be sent now to commission European for aprova0 final of the marketing, that occurs typically inside of 60 the 90 days. After aprova0 of the marketing, Adenuric(R) will be changedded, since 1964, the first significant alternative of the treatment for the available chronic hyperuricaemia to the patients of gout.

Adenuric(R) must be indicated for the treatment of the chronic hyperuricaemia for the circumstances where deposition of urate has occurred already (history including, or presence of, tophus and/or arthritis gouty). The recommendations detailed for the use of this product will be described in the summary of the characteristics of the product (SPC), to be made available later that medication receives the authorization from the marketing of commission European.

A time that the product receives its authorization from the marketing and its price is agreed, Febuxostat will be introduzdo in the market for Ipsen in France under the name of Adenuric type(R). It are of France, commercialisation of the product will be partnered.

Jean-Luc Blingard, president and main executive officer of Ipsen, said, “we are very proud to receive this positive opinion for Adenuric(R) from the EMEA, and look at onward to bring this new molecule to introduce in the market, during aprova0 of commission European. This innovative drug opens way for more than the first main treatment of gout 40 years. It confirms the ability of Ipsen to continue to severely bring to the important new options of the treatment of the market for illnesses debilitating.”

On Adenuric(R) (febuxostat)

Gout, a particularly painful type of arthritis, is the arthritis most frequent in the men. Elevated of acid uric in the body is caused by levels: hyperuricaemia. Febuxostat, a verbal one, a time that-daily medication, is one non-non-purine of the novel, selective inhibitor of oxidase of xanthine studied for its effect in lowering levels of acid uric of serum (its) in the patients with gout. Febuxostat is permitted the Ipsen for Europe Teijin limited Pharma, Tokyo.

The submission of I includes two the industry the greater of the sponsored studies to date to study the treatment of chronic patients of gout. The objective of the chronic treatment of gout is for guidelines of EULAR (it binds europia of meeting rheumatism) to reduce and to keep 6 levels of its below of mg/dL. Febuxostat demonstrated the superior ability to lower and to keep in the patients, acid uric of serum in an inferior of the the 6 level mg/dl compared with the conventionally used doses of allopurinol (febuxostat 80 and magnesium 120: 51 & 63 % of resp. against allopurinol: 22%). Beyond, a study of phase III it showed that the patients of gout with the soft one to moderate impairment renal (creatinine of serum > 1,5 -?2.0 mg/dl) had respectively had a tax of reply of 44 and 45 % with febuxostat 80 and magnesium 120.

The release of the CHMP press can be reached in http://www.emea.europa.eu.

In 2003, Ipsen entered in a partnership of the research and the development with Teijin limited Pharma, in the company of the nucleus of the pharmaceutical business and home of the group of Teijin of healthcare. The group of Teijin is a Japanese industrial conglomerate that is specialized in the businesses of staple fibres, the films, plastics and the technology of information (IT) as.well.as pharmaceuticals and healthcare home. This partnership has covered the development and commercialisation subsequent of the four of products of Ipsen for Teijin Pharma in Japan and development and the marketing for Ipsen in Europe (that is europias union and Russia) of febuxostat, a possessed for Teijin Pharma and known product as TMX-67.

On Ipsen

Ipsen is a pharmaceutical group directed innovation of specialty international with on the 20 products in the market and a total team of employees worldwide of almost 4.000. The strategy of the development of the company is based on a combination of the products in whitened areas therapeutic (oncology, endocrinology and disorders to neuromuscular) that they are drivers of the growth, and the preliminary products of the care that significantly contribute its financing of the research. This strategy is also supported by one active politics of the partnerships. The position of its four centers of the research and the development (Paris, Boston, Barcelona, London) gives to the group a competitive edge in gaining the access to the main teams of research of the university and to the highly qualified staff. In 2006, the expenditure of the R&D era?178.3 million, that is 20,7% of vendas consolidated, that atingiram?861.7 million when the total incomes atingiram?945.3 million (in IFRS). 700 peoples in the R&D are dedicated to the discovery and the development of innovative drugs for the patient care. The parts of Ipsen are negotiated in the segment of Eurolist for EuronextTM (the code conserved in supply: IPN, ISIN code: FR0010259150). The parts of s of Ipsen ‘ are eligible of “the o to the Rglement Diffr” (”SRD” Systme) and the group is part of the index of SBF 120. For more information in Ipsen, it visits our Web site in http://www.ipsen.com.

For ahead-looking at indications

The contained indications and targets for ahead-looking at in this are based on current opinions and assumptions of the management of Ipsen. Such indications involve the known and unknown risks and uncertainties that can make with that the real results, performance or events differ materially from those anticipated ones in this. Moreover, the process of the research and the development involves diverse periods of training in each one of that it has a substantial risk that the group will not obtain its objectives and will not force them to abandon its efforts in the respect of a product where invested significant additions. Consequently, the group cannot be certain that the favorable results gotten during experimentations pre-clinics will be confirmed subsequently during clinical experimentations, or that the results of clinical experimentations will be enough to demonstrate the safe and efficient nature of the concerned product, or that the authorities regulatory will be satisfied with the data and the information supplied by the company. Ipsen all contradicts express the obligation or to undertake to bring up to date or to revise any indications looking at forward, the targets or the estimates contained in this release of the press to reflect all the change in the events, the circumstances, the assumptions or the circumstances where indications are based, unless required thus for the applicable law. The business of Ipsen is subject to the sketched factors of risk in its filed originals of the information with the French financiers of the DES MarchsAutorit.

Europia Agency Of The Medicines

Savient Pharmaceuticals, Incorporation (NASDAQ:SVNT), positive results you add announced for endpoints secondary of efficacy in the two replicate studies of phase 3 for Puricase(R)(pegloticase) for gout of treatment-fails. The results were favorable for the effect of the treatment in the clinical results evaluated by the reduction in the number of soft and swelled junctions, and in the improvement in the patient they had told the results (PRO) as measured for Curto Form-36 (SF-36) and the questionnaire of the evaluation of the health - index of the inability (HAQ-DI). These endpoints had been evaluated in an analysis pooled daily pay-specified of the two replicate studies and are told for Inteno–Tratam the population. The improvement told in these results was clnica significant as definitive for the daily pay-specified definitions.

The company previously told that pegloticase if had found with endpoint preliminary daily pay-specified of efficacy, that is normalization of acid uric of the plasma for each week two and of the each administration of the dose of four weeks, independently, in each one of the 3 two-phase studies. Beyond, arm of the dose of two weeks of magnesium 8 each reached the meaning statistical against placebo in the analysis pooled daily pay-specified, one endpoint secondary, in the ratio of the patients who had had “a complete reply” for elimination of tophi of gout. The effect of the treatment of pegloticase in gout is widened, one secondary other endpoint, was told as a favorable numerical trend in both the arms of the treatment against placebo, but no arm of the treatment reached the meaning. The evaluation of the security through the 3 two-phase studies was told to be favorable and to have shown that the only signal of adverse security was the occurrence of reactions of infusion. Seven patients (2/85 in the arms of the Q2 week, 5/84 in the Q4 week if set) had had a total of 11 severe reactions of infusion (pain of the cramps, the back part or box of the muscle). Approximately 25 percent of all the patients in the arms of the treatment Q2 and Q4 had tried a soft or moderate reaction of infusion.

Following in these data previously told, the additional analysis showed that the meaning statistical stops of one each treatment of four weeks the arms of each week two and against placebo estve obtained stops:

- a reduction in the number of soft and swelled junctions
- a reduction in the number of soft junctions
- an improvement in the global evaluation of the physician (a visual analogous scale of 10 cm)

For both the groups of the treatment, the improvement degree was greater for acid the definite patients as responders uric of the plasma of that non-responders stops, but non-responders acid uric had seemed to also show the improvement against placebo. A additional analysis of that it finds is ongoing.

Two told instruments patient of the results had been used in the program of pegloticase, the short Form-36 (SF-36) and in the questionnaire of the evaluation of the health ” Index of the inability (HAQ-DI), that rheumatic had been used extensively in studies of rheumatology to evaluate clnica the significant change in some illnesses. The results of the experimentations of phase 3 show to that one in the analysis pooled daily pay-specified, both the arms of the treatment had reached the meaning statistical for the improvement against placebo for physical component countings SF-36. The form Arthritis-Especfico SF-36 of the index of the health also demonstrated estatstica to the significant improvement against placebo for both the arms of the treatment and showed another acid time that non-responders uric of the plasma had exactly had the improvement against placebo. The corporal scale of pain SF-36 also demonstrated to the meaning statistical for both the arms of the treatment against placebo and also showed that non-responders acid uric of the plasma had seemed to only improve but on the half as.well.as responders.

The results of the evaluation of HAQ-DI in the pain of the arthritis had shown to estatstica the significant improvement against placebo for the group of the dose of the Q2 week. Proper evaluation of the patient of its to function total, a component of the HAQ-DI, shown that both the arms of the treatment had reached estatstica the significant improvement against placebo.

“these results supply to the valuable evidence of the clinical benefit in our submissions regulatory upcoming and expect to be presented in the full detail in forums scientific futures and publications pair-magazines,” indicated Zeb Horowitz, M.D., Mr. VP and main medical officer. “the force of the evidence of the two experimentations of the GOUT has the potential to change the doctors of the way and the patients see gout of treatment-fail, a sight centered currently almost exclusively in the unsuccessful control of acid uric and the acute relief symptomatic of gout painful is widened, gradually leading the illness each more advanced time. In the light of the data of pegloticase, the patients of treatment-fail of gout and its doctors have the reason to wait for a better option of the treatment.”

The company is programmed to have a meeting of pre-BLA with the division resells of the administration of the food and the drug of United States (FDA) April in 17, 2008 and in plants to file the BLA with that the thus practicable FDA following the meeting of pre-BLA based in the positive results of its experimentations of phase 3.

On Puricase(R) (Pegloticase)

Puricase is pegylated oxidase mammalian recombinant of urate in the development to control the hyperuricemia and its clinical consequences in the patients for who the conventional therapy is contraindicated or had been inefficacious. The 3 two-phase experimentations pivotal had evaluated the security and efficacy of a course of six months of the therapy of pegloticase in the patients with gout of treatment-fails under the auspices of a special evaluation of the protocol of the administration of the food and the drug of United States. Savient permitted right worldwide to the related technology the PuricaseDuque Universidade and Mountain Mountain View Pharmaceuticals, Puricase Incorporation is a registada registered mark of pharmaceuticals of the Mountain View, Inc..

On The Population Of The Gout Of Tratamento-Falha

Approximately three to the Americans of five-million suffer from gout, many of who the experience only limited the success in the management in the long run of its painful symptoms. Inside of this group, us we esteem that allopurinol, mainstay of the therapy for the control of acid uric, is contraindicated or we do not obtain the appropriate success approximately therapeutic in dosages in the 25,000 100,000 patients, meaning that today the ten of the thousands of patients of gout do not have no efficient option of the treatment. It is for these patients of treatment-fails that pegloticase offers to potential an original benefit and for which the product was granted to the assignment orphan of the drug.

On PharmaceuticalsSavient, Inc..

Pharmaceuticals of Savient is a connected biopharmaceutical company in developing and distributing the products pharmaceutical that whiten medical necessities of unmet in niche and in wider markets. The candidate of the development of product of the company, Puricase (pegloticase) for gout of treatment-fails, told 3 positive clinical data of phase 1, 2 e. The patient who dosing in the clinical studies of phase 3 started in June 2006; the patient register was finished in March 2007; e the clinical studies of phase 3 had been finished in October 2007. Pegloticase changedded official the generic name for Puricase attributed for the USAN advice that substitutes the previously used name of the Peg-uricase. The tried team of the management of Savient is committed to advance its plumbing and to in- expand its portfolio of the product for composites being permitted of the late-period of training and to explore the chances of co-co-promotion and the co-development that fit the skill of the company in pharmaceuticals and in biopharmaceuticals of specialty with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (tablets of oxandrolone, USP) CIII in And U.. A additional information in Savient can be reached visiting: http://www.savient.com.

For Diante-Olhando the Language

It is important to write down that in the report these results of the preliminary the company is telling to its sights and opinions regarding the preliminary data and that the company cannot foresee as the FDA or other authorities regulatory summer or will consider the data in top of the revision, or as some data-set one of will be translated the language of the label, if approved. The FDA typically leads its proper analyses of the series of data of originals and possibly it can come to the different conclusions of that Savient reached. Moreover, the data told here are given preliminary since these are resulted initial, to be analyzed still extensively for inconsistencies and possible errors.

This release of the notice will count ahead-to look at the indications that are citizens to the determined risks, trends and uncertainties that could make with that the real results and accomplishments differ materially from those expressed in such indications. These risks, trends and uncertainties are in some examples beyond the control of Savient. The words as “they anticipate,” “believe,” “estimative,” “wait,” “intend,” “plant,” “” and other similar expressions help to identify ahead-to look at indications, even so all the indications for ahead-looking at do not contain these words identifying. These indications for ahead-looking at involve important risks and uncertainties and are based on expectations, assumptions, estimates and current projections on the business of Savient and the industries pharmaceutical biopharmaceutical and of specialty where Savient if operates.

For ahead-looking at the indications in this release of the notice they include, without limitation, the indications regarding the results clinical experimentations pivotal of phase 3 of the month of Savient of two six for Puricase(R) (pegloticase), of the filling of an application of the license of Biologics with the FDA and of the absence of other therapies to treat gout. The important factors the one that can affect the ability of Savient to obtain the substances directed in these indications ahead-to look at includes, but it is not limited, the price conserved in supply of Savient and the conditions of market, is slow or the imperfection in developing Puricase (pegloticase) is slow in the accomplishment or the imperfection to obtain aprova0 of the FDA of Puricase (pegloticase), the difficulties to expand the portfolio of the product of Savient with in-permitting, the fluctuations in tests standards of purchase of Oxandrin(R), potential future returns of Oxandrin or other products, Savient that continue to incur substantial liquid losses for the future foreseeable, difficulties in getting the financing, the potential development of alternative technologies or more efficient products for the competitors, reliance in third-leaving to manufacture, to introduce in the market and to distribute Savient the products, economic, politician and another one risk associated with extrangeiras operations, risks to keep the protection for the copyright of Savient, risks of an adverse determination in litigation ongoing or argued future of the copyright, risks associates with the strict regulation of the government of the biopharmaceutical industry and the other risks or referenced in our more recent annual report in the form 10-K, in the quarterly report in the form 10-Q and the other reports of the chain, each one filed by Savient with as. Savient cannot really obtain the plants, the intentions or the expectations divulged in indications for ahead-looking at of Savient. The real results or events could differ materially from the plants, the intentions and the expectations divulged in the indications for ahead-looking at that Savient makes. The shareholders do not have to ahead- place reliance improper in the indications for being looked at, that they only speak regarding the date of this release of the press. The indications for ahead-looking at of Savient do not reflect the potential impact of nenhuns future acquisitions, mergers, common disposals, risks or investments that Savient will be able to make. Savient does not assume no obligation to bring up to date nenhumas indications for ahead-looking at.

PharmaceuticalsSavient, Inc..

In accordance with a recent study it published in bmj.com, the soft men whom they drink drunk sugary and they eat fructose have a risk increased of gout.

Gout is an illness caused for an accumulation of acid uric in the blood (hyperuricemia) that it provokes a reaction inflammatory in fabrics and the junctions. He is frequent painful and it is the most common in the men 40 older years of age and. On last the few decades, levels of gout in the United States had folded. This increase coincided with the levels highest of soft drinks and consumption of fructose - fructose is a simple sugar that increases acid levels uric.

Generally, the patients with gout are said to restrict the consumption of the products of the alcohol and meat such as the liver and kidney that calls contain organic composites purines. Sugary is unconventional to restrict the soft drink consumption.

The investigators in And U. and Canada had analyzed the linking enter the entrance of the sugar - through soft drinks and of fructose in the food - and the risk of gout. To follow on 46.000 men (with none history of gout) aged 40 or excess per 12 years, the data compiled investigating in the food entrance of more than 130 foods and regular drinks, including drunk soft and of the diet as well as the fruits and the fruit juices that of course are raised in fructose. Each two years later that the start of the study, the data collected investigating in the weight, use of medications, and medical circumstances. During the period to 12-year, 755 cases recently diagnosised of gout had been recorded.

Findings main includes:

• Because the entrance of the sugar sweetened the increased soft drinks, the risk of gout increased
• Compared with the men who had consumed less of one serving of soft drinks for the month, those that they had consumed 5-6 servings per the week had raised significantly its risk of gout for 29%
• Those that they had consumed two more or servings per the day had increased significantly its risk for 85% compared with those that had consumed less of one that it serves for the month
• The soft drinks of the diet had not been associates with the risk of gout
• The rich foods in fructose such as fruits and fruit juices had been associates with the risk increased of gout

The results of the study are independent of other factors of risk of gout such as the index of the mass of the body, age, use of diuretics, pressure of blood, consumption of the alcohol, and diet. The authors warn that findings regarding the fruit and of fruit juices must com.cuidado to be interpreted, if keeping in the mind that the consumption of the fruits and vegetables was associated with the prevention of the pressure of raised blood, of the illness of heart, the course, and the some cancers.

Soft drinks, consumption of fructose, and the risk of gout in the men: Perspective study Of the Cohort
Choi, Hyon and Curhan, Gary
bmj.com, January 31, 2008
doi:10.1136/bmj.39449.819271.BE

Estale to see in line the article here

Writing close: Peter M Crust, Milliampere
Copyright: Medical notice Today
Not to be reproduced today without permission of the medical notice

“a greater risk of gout of the soft drinks ‘ of that the alcohol ‘” read headline in the daily telegraph today. It told that “to drink too much many soft drinks and fruit juices sugary can substantially increase the risk of gout”. Gout can extremely be painful and is caused by a configuration above of acid uric that it is crystallized in the junctions. Acid uric is given form for damages of purines that they of course occur in the body as.well.as in the diet. Traditional, the advice is to prevent the red meat and the alcohol because they have high levels of purines and can make gout worse. However the said telegraph “the risks associated with these drinks was higher of the one than with determined types of alcohol”.

This history is based on a study well-designed in more than 46,000 men who had found those that had drunk two or more soft drink cans that one the day increased its gout of the risk for 85 percent had compared with the men whom they had less drunk of the one than one soft drink one month. It supplies however to one another reason because to drink drunk fizzy sugary is not good for its health.

Of where history came? The removal cilindro/rolo Hyon Choi and Gary Curhan das university of British Colombia and Harvard carried through this research. The study it was financed in the part for the national justinian codes of the health and pharmaceuticals of the TAP. It was published in the British medical periodical pair-I coat.

That type of the scientific study was this?

This study it was part of a great perspective study of cohort that it looks at the health of the masculine professionals of health. This study it enlisted 51,529 aged men 40 the 75 in 1986 and the investigators had selected the 46,393 men who had not been with gout in the beginning of the study.

In top of enrolment, the men had fulled for are questionnaires standard on its consumption of the food and the drink, including its food and drink consumption fizzy and drinks that contain fructose, a type of sugar found in drinks fizzy, the fruit, and the products such as syrup of maize. The men had supplied to information updated on its consumption of the food and the drink each four years.

Each, the men had been two years emitted to a questionnaire, that asked if they had been diagnosised with gout. As a questionnaire with detailed questions was affixed the men who had told a diagnosis of gout. This allowed that the investigators confirmed the diagnosis based on accepted criteria of the American college of rheumatology, but one has not tested of blood. The study it lasted per 12 years.

The investigators had compared then the risk to develop gout in the men with the different levels of the average consumption fizzy of the drink and fructose on the period to 12-year. They had adjusted these analyses for the factors that had been able to affect resulted, such as the consumption of the men of the alcohol, meat, seafood, vitamin C and vegetal rich in purine, its use of determined medicines (diuretics), the massive index of the body, a total amount of consumed energy, the age, and the presence of the pressure of high blood or the chronic imperfection of kidney.

What were the results of the study?

Approximately 1,5% of the men (755) they had developed gout during the study. The men whom they had drunk drunk more fizzy were more probable to develop gout of that those that had drunk few drinks fizzy.

The men who had had more of the one than one drink fizzy the one day had increased its risk for 45%; the two or drinks one the day had more increased the risk for 85%, compared with the men whom they had less drunk of the one than one drink fizzy one month. The drinks fizzy of the diet had not increased the risk of gout. The peoples with the the most raised entrance of fructose had folded its risk of gout compared with the those with the entrance lowest.

That interpretations the investigators had extracted of these results?

The investigators conclram that consuming non-it makes diet drunk fizzy and fructose increases the risk to develop gout. They say that the increase in the risk seen with softer two drinks or one the day slightly more is raised of the one than that visa with alcoholic espritos.

What the service of the NHS knowledge makes of this study?

This age a study well-designed and lead that had diverse forces, including its great size, the perspective project, its use of criteria accepted for the diagnosis of gout, and the use of repeated questionnaires of the food. Some points to consider when interpreting the study they are that one:

- as with all cohort it studies, is the possibility there that the results are affected by disequilibria between the groups to the exception of this of the interest (consumption fizzy of the drink). The authors had tried to even so adjust for these, that the confidence in the results increases, the possibility that some another factor is playing a paper cannot be governed for is completely.

- professional of health and mainly white looked at the men who were, this of this study can explain the relatively low total risk to develop gout and only imply that these results can differ in the women or for other groups of the men.

- even so fructose either contained in the fruit and fruit juices, the benefits to eat the fruit are probable to compensate distant the risk to develop gout. To reduce the entrance of fructose of the sources of the non-fruit, such as drunk fizzy, is a better strategy to reduce the risk of gout.

This study it supplies however to one another reason because the drinks sugary, fizzy are not good for its health.

Linkings to headlines

Soft drinks ‘ greater risk of gout of that the alcohol ‘. The Daily Telegraph, February 1 2008
On drinks of Fizzy to gout. The Times, February 1 2008
The PNF of Fizzy increases the risk of gout. The Sun, February 1 2008

Linkings to science

Soft drinks, consumption of fructose, and the risk of gout in the men: perspective study of cohort.
Choi HK, Curhan G.
2008 BMJ January 31

This notice comes of the NHS choices

The arthritis are the most common cause of the inability in the United States. On the 25 following years as the baby growth the generation continues to age, the toll of this illness will scale. To have a picture clear of burden being appeared of the illness and its impact in the care of health of our nation and systems of the public health, esteem prevalence of the illness - the number of the peoples affected for some form of the arthritis - is critical.

Workgroup national of the data of the arthritis was given form to supply to an only source of national data in some circumstances rheumatic. Supported for the national justinian codes of the health, the centers for the illness control, the American college of rheumatology, and the foundation of the arthritis, its connoisseurs of epidemiology use the better available studies to determine prevalence of the illness, they evaluate the potential impact of the illness, and identify openings in our understanding of taxes of the illness, populations, and social implications. In the introduction of January 2008 of the arthritis & rheumatism, the group presents its more behind report in the state bothering of the arthritis in America.

Based in analyses of estimates of the population of the department of census, answers of the national examinations, and of findings of the countings of studies community-based through the country, workgroup national of the data of the arthritis offers to a snapshot unsettling of the 2005 (and future) burden of the arthritis. Some findings keys of the study include:

* Total Arthritis: More than 21 percent of adults of United States - on 46 million peoples - has the arthritis or to another condition rheumatic diagnosised by a doctor. Two teros of patients of the arthritis are almost new of 65. More than 60 percent are women. The taxes of the illness are similar for whites and African-Americans and more highly of the one than the taxes for hispanics. Per 2030, the number of the peoples with arthritis is projected to increase the 67 million almost - an increase of 40 percent.

* Osteodistrofia (Oa): 27 million almost American suffer from OA, the most common type of arthritis, an increase of the 21 million esteem in 1990. Arising itself with age, prevalence of the OA also affects the hands and the knees of the women more frequently of the one than men and African Americans more frequently of the one than white.

* Arthritis Rheumatoid (RA): This adult 1,3 destructive illness inflammatory confusing and affects million, for low of estimate 1990 of 2.1 million - in the part due to more restrictive criteria of the classification but also because of a real drop in prevalence. The trends show that the average age of the diagnosis increased the exceeding time firmly, suggesting that the RA if is transforming an illness of older adults.

* Gout: In 2005 3 million approximately American had had gout in the 12 preceding months, above of the estimate of 2.1 million in 1990. Arthritis inflammatory on to acid uric elevated in the blood, gout tends to be more prevalent enters older men and more prevalent in older African American males of the one than in older white or Latin American males.

* Arthritis Juvenile: Based in recent data of the visits ambulatory pediatric of the care, the 294,000 children esteem between the ages of infancy and 17 are affected by the arthritis or other circumstances rheumatic.

* The report also includes estimates 2005 of prevalence for the fibromyalgia, spondylarthritides, erythematosus systemic of lupus, the sclerosis systemic, syndrome of Sjgren, syndrome of carpal tunnel, the arteritis of the stack of the polymyalgia rheumatic/giant, and the back pain and of throat.

“to measure prevalence of the arthritis poses many challenges,” recognize spokesperson of workgroup of the data of the national arthritis and the member, Dr. Charles G. Helmick. For departure activators, some circumstances are episodic and others do not have no definition standard of the case. Beyond, the estimates for some circumstances rheumatic trust small or older studies with results that had not been able to apply the current population of United States. However, this report not only calls the attention to prevalence raised the arthritis nationwide and burden increasing in our care of health and systems of the public health, but also in the industry and the society American.

The article was adaptou today for Medical Notice of the release of the original press.

Article: “estimates of prevalence of the arthritis and other conditions rheumatic in the United States, of part I and part II,” Charles G. Helmick, David T. Felson, Reva C. Lawrence, Sherine Gabriel, Rosemarie Hirsch, C. Kent Kwoh, Matthew H. Liang, Hilal Maradit Kremers, Maureen D. Mayes, Peter the Merkel, Stanley R. Pillemer, John D. Reveille, John H. Pedra, Lesley M. Arnold, Hyon Choi, Richard the Deyo, marc C. Hochberg, gene G. Hunder, M. Jordo, Jeffrey N. Katz, and Frederick WolfeJoanne for workgroup national of the data of the arthritis; Arthritis & Rheumatism, January 2008, 58:1.

Source: Amy Molnar
Wiley-Blackwell-Blackwell

Savient Pharmaceuticals, Incorporation (Nasdaq: SVNT) announced the conclusion of the parcel of the in-life of its two clinical experimentations of phase 3 pivotal for Puricase(R) (pegloticase) in the patients with gout of treatment-fails, an indication orphan. Puricase is pegylated oxidase mammalian recombinant of urate that he is being developed to control the hyperuricemia and its clinical consequences in the patients for who the conventional therapy is contraindicated or was inefficacious. In this time therapeutic for the management of patients of gout does not have no alternative option of treatment-fails to the exception of the relief symptomatic.

“the conclusion of the parcel of the in-life of the studies of phase 3 is an important noticeable landmark for the company and for patients of gout of treatment-it fails,” commented Christopher clement, president and main executive officer. “we believe that the level of the patient commitment during the period of the study and the high tax of the register our open protocol of the extension of the label underscores the critical vacuum options of the treatment for the patients who suffer from this circumstance the one that Puricase can bonanza be directed. Because we in move them onward on diverse following weeks, us we will focus our resources in mounting and analyzing the data of phase 3. We remain in the track to make our following public indication regarding the studies of phase 3 when we tell the high-line resulted in December.”

The 3 two-phase experimentations pivotal had evaluated the security and efficacy of a course of six months of the therapy of Puricase in the patients with gout of treatment-fails, under the auspices of a special evaluation of the protocol of the administration of the food and the drug of United States. The 3 enclosed two-phase studies on 200 patients in more than 50 clinical places through the states, of joined Canada and Mexico. The studies had consisted of two replicate protocols; each randomized, double-blinded, controlled study placebo of six months of duration where Puricase or placebo had been managed by one infusion intravenous two-hour. Approximately 110 patients randomized in each study and a total of 212 patients received to the little one dose from medication from the study (Puricase or placebo). Each study it had three arms: placebo, magnesium of Puricase 8 managed each two weeks, or the magnesium of Puricase 8 managed each four weeks. The end to keep the curtain to the attribution of the treatment, all the patients had received one infusion intravenous each two weeks.

In a base of rolling, because the patients had finished its participation in the studies of phase 3, all the finished patients had been invited to register itself in an open protocol of the extension of the twelve-month label that offers a choice between three options: comment, where the patients could use all the drug of gout except Puricase; Magnesium of Puricase 8 each two weeks; or Puricase 8mg each four weeks. After six months in the open protocol of the extension of the label, are allowed the patients to commute the arms. Almost all the patients who had finished the experimentations of phase 3 opted to register in the open extension of the label, being selected each week two, or arms of each treatment of the Puricase magnesium of four weeks 8. The open protocol of the extension of the label is ongoing. An open protocol of the extension of the label of follow-on for others twelve months is gliding, not obstante if the patients choose to continue to receive Puricase or if they enter in the arm of the comment of the study.

“we are very pleased with the conclusion of the program of phase 3 and we look at onward to study the series of data of,” we said Zeb Horowitz, M.D., vice-president of Mr. and main medical officer. “in the parallel, us we will continue to observe prxima our patients in the open protocol of the extension of the label in such a way to learn how much can on the security and efficacy of the use in the long run of Puricase, and to monitor the clinical results for the patients whom they had chosen to interrupt the administration of the dose of Puricase. It is our hope that if the clinical benefit beyond the control of acid uric will be reached with the treatment of Puricase, such clinical benefit could prove to be durable. This would be a wonderful result for the patients who have limited currently or nenhumas options therapeutic.”

Separate, the company announced that pegloticase if transformed official the generic name for Puricase attributed for the USAN advice, substituting the previously used name of the Peg-uricase.

On The Gout

In accordance with the national justinian codes of the health, gout explains 5 approximately percent of all the cases of the arthritis and is one of the most painful illnesses rheumatic. Million has 5 approximately American that they suffer with gout, and of that one, has approximately 25.000-100.000 patients of treatment-fails for who the conventional therapy is contraindicated or estve inefficacious. Gout results of the crystal deposits needle-like of acid uric in the fabric connective and the junctions. These deposits lead to the arthritis inflammatory, that cause the common swell, redness, heat, pain, and rigidity and damages to the affected junctions. In the patients for who the conventional therapy is contraindicated or was inefficacious, the illness can become chronic, gradually worsen and cause widening debilitating of pain and the swell, development of tophi, loss of the common functionality, dysfunction renal and/or the rocks of kidney.

On PharmaceuticalsSavient, Inc..

Pharmaceuticals of Savient is a connected biopharmaceutical company in developing and distributing the products pharmaceutical that whiten medical necessities of unmet in niche and in wider markets. The candidate of the development of product of the linking of the company, Puricase(R) (pegloticase) for gout of treatment-fails, told given positive physicians of phase 1 and 2. The patient who dosing in the clinical studies of phase 3 started in June 2006; the patient register was finished in March 2007; e the clinical studies of phase 3 had been finished in October 2007. The tried team of the management of Savient is committed to advance its plumbing and to in- expand its portfolio of the product for composites being permitted of the late-period of training and to explore the chances of co-co-promotion and the co-development that fit the skill of the company in pharmaceuticals and in biopharmaceuticals of specialty with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (tablets of oxandrolone, USP) CIII in the Puricase United States is a registada registered mark of pharmaceuticals of the Mountain View, Inc.. A additional information in Savient can be reached visiting: http://www.savient.com.

For Diante-Olhando the Language

This release of the notice will count ahead-to look at the indications that are citizens to the determined risks, trends and uncertainties that could make with that the real results and accomplishments differ materially from those expressed in such indications. These risks, trends and uncertainties are in some examples beyond the control of Savient. The words as “they anticipate,” “believe,” “estimative,” “wait,” “intend,” “plant,” “” and other similar expressions help to identify ahead-to look at indications, even so all the indications for ahead-looking at do not contain these words identifying. These indications for ahead-looking at involve substantial risks and uncertainties and are based on expectations, assumptions, estimates and current projections on the business of Savient and the industries pharmaceutical biopharmaceutical and of specialty where Savient if operates.

Such risks and uncertainties include, but they are not limited, the price conserved in supply of Savient and the conditions of market, delay or the imperfection in developing Puricase(R) and other candidates of the product, the difficulties to expand the portfolio of the product of Savient with in-permitting, the introduction of the generic competition for Oxandrin(R), fluctuations in tests standards of purchase of the wholesalers, in potential future returns of Oxandrin or other products, Savient that continue to incur substantial liquid losses for the future foreseeable, difficulties in getting the financing, the potential development of alternative technologies or more efficient products for the competitors, reliance in third-leaving for manufacturing, to introduce in the market and to distribute many of products of Savient, economic, politician and of others risk associated with extrangeiras operations, risks of the protection keeping for the copyright of Savient, the risks of an adverse determination in litigation ongoing or future of the copyright, and the risks had associated with the strict regulation of the government of the biopharmaceutical industry. Savient cannot really obtain the plants, the intentions or the expectations divulged in indications for ahead-looking at of Savient. The real results or events could differ materially from the plants, the intentions and the expectations divulged in the indications for ahead-looking at that Savient makes. The shareholders do not have to ahead- place reliance improper in the indications for being looked at, that they only speak regarding the date of this release of the press. The indications for ahead-looking at of Savient do not reflect the potential impact of nenhuns future acquisitions, mergers, common disposals, risks or investments that Savient will be able to make. Except as necessary for the law, Savient does not assume no obligation to bring up to date nenhumas indications for ahead-looking at.

http://www.savient.com

Raised the acid levels uric in the blood are a precursor of gout, the arthritis inflammatory most common in men of the adult. One gives credit that the consumption of the coffee and the tea can only affect acid levels uric but a study estve lead to the date. A new large-scale study it published in the introduction of June 2007 of the care of the arthritis & the research (http://www.interscience.wiley.com/journal/arthritiscare) examined the relationship between the coffee, the tea, the acid entrance of the caffeine, and levels uric and found that the consumption of the coffee is associated with lower the acid levels uric but that this seems to have to the components to the exception of the caffeine.

The coffee is one of drinks more extensively consumed in the world; more than 50 percent of the Americans drink it in the average tax of 2 cups per the day. For cause of this spread out consumption, its potential effect have important implications for the public and individual health. Lead for Hyon K. Choi, of the university of British Colombia in Vancver, Canada, the current study national examination of the examination of the health and nutrition of United States was based in third, lead between 1988 and 1994. It included on 14.000 men and women to the little 20 years old who assented in one exam medical where the specimens of the blood and urine had been gotten. The consumption of the coffee and the tea was determined based on answers to a questionnaire of the food that evaluated the entrance on the preceding month. The investigators had esteem the amount of caffeine for the cup of the given coffee or the tea having used of the department of United States of agriculture.

The results had shown that the levels of acid uric in the blood had diminished significantly with increasing entrance of the coffee, but not with entrance of the tea. Beyond, it did not have no association enters the total entrance of the caffeine of drinks and acid levels uric. These similar results were queles found no only topical preceding study no, that it was lead in Japan. Interesting, it had an association between the consumption of the coffee decaffeinated and acid levels uric. “these findings suggest that the components of the coffee to the exception of the caffeine contribute to the observed inverse association enter the acid entrance of the coffee and levels uric,” the state of the investigators.

A recent study it found that the coffee was the levels lowest associates of peptide of C (a marker of levels of insulin). The investigators in the current study suggest that because has a strong relationship it enters the acid resistance of insulin and levels uric elevated, the levels diminished of insulin associates with the consumption of the coffee can lead to lower acid levels uric. The coffee is also a principal source of acid chlorogenic, one antioxidant strong, that it can improve the sensitivity of insulin. The aids chlorogenic of the acid one also inhibit absorption of glucose in intestine; in one another study that the coffee decaffeinated seemed it delays it absorption intestinal of glucose and the concentrations of the increase glucagon-as of peptide 1, that it is known well for its beneficial effect in secretion and the action of insulin. The investigators write down more more than its results could have to a effect of the found components of the non-caffeine in the coffee, that would also explain because the coffee affected acid levels uric but the tea not.

The article was adaptou today for Medical Notice of the release of the original press.

Article: “coffee, tea, and acid level uric of the consumption of the caffeine and serum: The third national examination of the examination of the health and nutrition, “Hyon K. Choi, Gary Curhan, care of the arthritis & searches, June 2007; 57:5; (DOI: 10.1002/art.22762).

Contact: Amy Molnar
John Wiley & Filhos, Inc..

The coffee is a habit for more than 50 percent of the Americans, whom they drink, in the average, 2 cups per the day. This drink extensively consumed regularly is investigated and debated for its impact in conditions of the health of cancer of chest to the heart illness. It enters its complex effect in the body, the coffee or its components had been on to lower insulin and acid levels uric in a short-term or cross-section base. These and other mechanisms suggest that the consumption of the coffee can affect the risk of gout, the arthritis inflammatory more prevalent in males of the adult.

To examine as the consumption of the coffee aggravate could or to protect of meeting to this common land and condition excruciatingly painful, investigating in the center of research of the arthritis of Canada, university of British Colombia in Canada, Brigham and hospital of the women, the medical school of Harvard, and the school of Harvard of the public health in Boston history of gout in the base line had lead a perspective study in 45.869 men on age 40 with none. On 12 years of the continuation, Hyon K. Choi, MD, DrPH, and its associates had evaluated the relationship enter the entrance of the coffee and the incidence of gout in this population of the high risk. Its findings, characterized in the introduction of June 2007 of the arthritis & rheumatism (http://www.interscience.wiley.com/journal/arthritis), supply the evidence compelling that drinking the 4 or more cups of the coffee one the day the risk of gout for men reduces dramtica.

The subjects had been extracted of a study ongoing of one 50,000 masculine professionals of health, 91 percent of white, that if carried through between 40 and 75 years of age in 1986 where the project was initiated. To evaluate the coffee and the total entrance of the caffeine, the Dr. Choi and its team had used a questionnaire of the food-frequency, brought up to date each 4 years. Participants had chosen of 9 answers of frequency - varying of never the 2 4 cups for the week the 6 or more per the day - to record its average consumption of the coffee, of coffee decaffeinated, tea, and other victuals caffeine-containing, such as the glue and the chocolate.

Through one another questionnaire, the investigators had registered the 757 boxes recently diagnosised that meet with the American college of criteria of rheumatology for gout during the period of the continuation. Then, they had in the long run determined the relative risk of gout of incident for the divided drinkers of the coffee in 4 groups - less than 1 cup for 1 the 3 cups per the day, the 4 5 cups of the day, for the day, and 6 or more cups per the day - as well as for regular drinkers of coffee decaffeinated, tea, and others caffeinated drunk. They had also evaluated the impact of other factors of risk for gout - massive index of the body, history of hypertension, use of the alcohol, and a diet raised in the red meat and foods of dairy high-fat between them - in the association between the consumption of the coffee and gout enters participants of the study.

More significantly, the data had disclosed that the risk to develop gout diminished with increasing consumption of the coffee. The risk of gout was 40 percent lower for the men who had drunk the 4 5 cups the one day and 59 percent lower for the men that had drunk 6 or more cups one day of that it stops the men who had never drunk the coffee. Decaffeinated also had a modest inverse association with consumption of the coffee. These findings were independent of all remaining factors of risk for gout. To drink of the tea and the total entrance both of the caffeine had been shown not to have no effect in the incidence of gout between the subjects. In the mechanism of these findings, the Dr. Choi speculates that the components of the coffee to the exception of the caffeine can be responsible for the benefits of the gout-prevention of the drink. Between the possibilities, the coffee will count acid chlorogenic of phenol, one antioxidant strong.

To more not prescribing 4 or cups one day, this can of the study helps the individuals to make a choice informed regarding the consumption of the coffee. “ours findings 40 years and older are more directly generalizable to the age of the men, population gout it more gout-prevalent, with none history of gout,” notes of the Dr. Choi. “given to the potential influence of hormones female in the risk of gout in the women and an increased paper of the dietary impact in acid levels uric between patients with gout existing, the studies perspective of these populations would be valuable.”

The article was adaptou today for Medical Notice of the release of the original press.

Article: of the “consumption coffee and risk of gout of incident in the men: A study, a “Hyon K. Choi, Walter Willett, and a perspective Gary Curhan, arthritis & rheumatism, June 2007; (DOI: 10.1002/art.22712).

Contact: Amy Molnar
John Wiley & Filhos, Inc..